Advertisement
Advertisement
U.S. markets open in 4 hours 56 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Jasper Therapeutics, Inc. (JSPR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.84-0.39 (-4.74%)
At close: 04:00PM EST
7.84 0.00 (0.00%)
After hours: 07:57PM EST
Advertisement

Jasper Therapeutics, Inc.

2200 Bridge Parkway
Suite 102
Redwood City, CA 94065
United States
650 549 1400
http://jaspertherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees22

Key Executives

NameTitlePayExercisedYear Born
Mr. William David LisPres, Exec. Chairman & CEO571.16kN/A1964
Dr. Judith Anne Shizuru M.D., Ph.D.Co-Founder, Chair of Scientific Advisory Board & Director250kN/A1956
Mr. Jeetinder Singh Mahal M.B.A.Chief Financial & Bus. Officer and Corp. Sec.445.45kN/A1972
Dr. Kevin N. Heller M.D.Exec. VP of R&D524.19kN/A1971
Dr. Susan Prohaska Ph.D.Co-Founder and VP of Operations & Program ManagementN/AN/AN/A
Dr. Carol ZoltowskiSr. VP of Regulatory Affairs & QualityN/AN/A1950
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Corporate Governance

Jasper Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement